Literature DB >> 19823871

Expression of nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues.

Gongyuan Zhang1, Qiao Zhang, Qinxian Zhang, Lei Yin, Shenglei Li, Kuisheng Cheng, Yunhan Zhang, Honghui Xu, Weidong Wu.   

Abstract

OBJECTIVE: To determine the expression of nucleostemin (NS), epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) mRNA in human esophageal squamous cell carcinoma (ESCC) tissues and their association in a human ESCC cell line.
METHODS: The expression of NS, EGF and EGFR mRNA was determined in paired normal esophageal and ESCC tissues of 62 patients using in situ hybridization. The association between NS and EGF or EGFR was examined using immunoblotting and real time polymerase chain reaction in a human ESCC cell line transfected with NS siRNA or treated with a selective EGFR inhibitor.
RESULTS: In normal esophageal and ESCC tissues, the positive detection rates were 21.0% (13/62) and 69.4% (43/62) for NS mRNA staining, 40.3% (25/62) and 77.4% (48/62) for EGF mRNA staining, and 30.6% (19/62) and 75.8% (41/62) for EGFR mRNA staining, respectively. These results indicated that NS, EGF and EGFR mRNA expression was upregulated mostly in ESCC tissues. Moreover, the expression of NS, EGF and EGFR mRNA was positively correlated with tumor grade, invasion and lymphatic metastasis of ESCC cells. NS mRNA was co-expressed with EGF and EGFR mRNA in ESCC tissues. The in vitro studies using a human ESCC cell line showed that knockdown of NS with NS siRNA significantly reduced EGF and EGFR expression. However, inhibition of the EGFR kinase activity with a specific EGFR kinase inhibitor had minimal effect on NS expression.
CONCLUSION: The upregulation of NS, EGF and EGFR mRNA frequently occurs in ESCC tissues and is associated with malignancy of human esophageal squamous tumors. NS is required for EGF and EGFR expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19823871     DOI: 10.1007/s00432-009-0693-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  35 in total

1.  Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.

Authors:  Michael P DiGiovanna; David F Stern; Susan M Edgerton; Steve G Whalen; Dan Moore; Ann D Thor
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

2.  Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2.

Authors:  Mu-Shui Dai; Xiao-Xin Sun; Hua Lu
Journal:  Mol Cell Biol       Date:  2008-04-21       Impact factor: 4.272

3.  Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas.

Authors:  I Porebska; A Harlozińska; T Bojarowski
Journal:  Tumour Biol       Date:  2000 Mar-Apr

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

Review 5.  Growth factors in progression of human esophageal and gastric carcinomas.

Authors:  K Yoshida; W Yasui; H Ito; E Tahara
Journal:  Exp Pathol       Date:  1990

Review 6.  Genetic steps in the development of squamous cell carcinoma of the esophagus.

Authors:  A M Mandard; P Hainaut; M Hollstein
Journal:  Mutat Res       Date:  2000-04       Impact factor: 2.433

7.  A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements.

Authors:  Mikihiko Kimura; Hitoshi Tsuda; Daisaku Morita; Takashi Ichikura; Sho Ogata; Shinsuke Aida; Yutaka Yoshizumi; Tadaaki Maehara; Hidetaka Mochizuki; Osamu Matsubara
Journal:  Virchows Arch       Date:  2004-07-28       Impact factor: 4.064

8.  Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification.

Authors:  Y Itakura; H Sasano; C Shiga; Y Furukawa; K Shiga; S Mori; H Nagura
Journal:  Cancer       Date:  1994-08-01       Impact factor: 6.860

9.  Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.

Authors:  Caroline J Witton; Jonathan R Reeves; James J Going; Timothy G Cooke; John M S Bartlett
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

10.  Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study.

Authors:  Akishi Ooi; Takuo Takehana; Xiaoling Li; Shioto Suzuki; Kazuyoshi Kunitomo; Hiroshi Iino; Hideki Fujii; Yasuhisa Takeda; Yoh Dobashi
Journal:  Mod Pathol       Date:  2004-08       Impact factor: 7.842

View more
  9 in total

1.  Concomitant upregulation of nucleostemin and downregulation of Sox2 and Klf4 in gastric adenocarcinoma.

Authors:  Malek Hossein Asadi; Ali Derakhshani; Seyed Javad Mowla
Journal:  Tumour Biol       Date:  2014-04-25

2.  Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma.

Authors:  Shi Liu; Jian Gong; Asahiro Morishita; Takako Nomura; Hisaaki Miyoshi; Joji Tani; Kiyohito Kato; Hirohito Yoneyama; Akihiro Deguchi; Hirohito Mori; Shima Mimura; Kei Nomura; Takashi Himoto; Kazushi Deguchi; Keiichi Okano; Kunihiko Izuishi; Yasuyuki Suzuki; Yoshio Kushida; Reiji Haba; Hisakazu Iwama; Tsutomu Masaki
Journal:  Exp Ther Med       Date:  2011-02-08       Impact factor: 2.447

3.  Association of PYGO2 and EGFR in esophageal squamous cell carcinoma.

Authors:  Meysam Moghbeli; Mohammad Reza Abbaszadegan; Moein Farshchian; Mehdi Montazer; Reza Raeisossadati; Abbas Abdollahi; Mohammad Mahdi Forghanifard
Journal:  Med Oncol       Date:  2013-03-03       Impact factor: 3.064

4.  Immunohistochemical study of doublecortin and nucleostemin in canine brain.

Authors:  E De Nevi; P Marco-Salazar; D Fondevila; E Blasco; L Pérez; M Pumarola
Journal:  Eur J Histochem       Date:  2013-03-20       Impact factor: 3.188

5.  Nucleostemin expression in invasive breast cancer.

Authors:  Takayuki Kobayashi; Kenkichi Masutomi; Kenji Tamura; Tomoyuki Moriya; Tamio Yamasaki; Yasuhiro Fujiwara; Shunji Takahashi; Junji Yamamoto; Hitoshi Tsuda
Journal:  BMC Cancer       Date:  2014-03-21       Impact factor: 4.430

6.  Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.

Authors:  Sreeraj G Pillai; Shunqiang Li; Chidananda M Siddappa; Matthew J Ellis; Mark A Watson; Rebecca Aft
Journal:  Breast Cancer Res       Date:  2018-01-02       Impact factor: 6.466

7.  Upregulation of GNL3 expression promotes colon cancer cell proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway.

Authors:  Xi Tang; Lang Zha; Hui Li; Gang Liao; Zhen Huang; Xudong Peng; Ziwei Wang
Journal:  Oncol Rep       Date:  2017-08-25       Impact factor: 3.906

8.  CALM1 promotes progression and dampens chemosensitivity to EGFR inhibitor in esophageal squamous cell carcinoma.

Authors:  Tao Liu; Xiujuan Han; Shutao Zheng; Qing Liu; Aerziguli Tuerxun; Qiqi Zhang; Lifei Yang; Xiaomei Lu
Journal:  Cancer Cell Int       Date:  2021-02-18       Impact factor: 5.722

9.  Prognostic significance of epidermal growth factor receptor in locally advanced esophageal squamous cell carcinoma for patients receiving chemoradiotherapy.

Authors:  Zhenhua Gao; Xue Meng; Dianbin Mu; Xindong Sun; Jinming Yu
Journal:  Oncol Lett       Date:  2014-02-13       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.